Observational Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Dec 28, 2016; 22(48): 10643-10652
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10643
Table 2 Age-group specific prevalence of gastrointestinal bleeding risk factors in overall population
20-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-7475-7980-84≥ 85 yr
Comorbid conditions
Peptic ulcer3.84%4.80%4.92%5.49%7.61%8.47%10.87%12.45%14.20%15.49%17.50%16.08%13.72%9.95%
Diabetes0.31%0.49%0.96%1.76%3.27%5.68%8.78%13.17%18.18%22.04%25.48%25.96%23.55%16.13%
Chronic liver disease2.17%2.99%3.74%4.40%4.76%5.99%7.55%8.68%9.09%9.03%8.01%6.91%5.65%3.96%
Chronic renal failure0.03%0.06%0.09%0.14%0.23%0.28%0.39%0.59%0.88%1.13%1.66%1.84%1.96%1.66%
Gastroesophageal Reflux disease6.02%8.34%8.88%9.92%13.22%13.63%17.18%19.11%22.11%22.85%23.93%20.94%17.29%11.43%
Concomitant drugs1
Aspirin0.03%0.08%0.13%0.42%1.15%2.65%5.66%10.21%15.55%19.84%24.26%25.57%25.15%19.66%
Clopidogrel0.01%0.01%0.03%0.09%0.27%0.56%1.10%2.13%3.66%5.18%7.23%8.59%9.41%7.19%
Cilostazol0.00%0.00%0.01%0.03%0.11%0.23%0.48%0.86%1.36%1.98%2.59%3.09%2.96%2.17%
NSAIDs0.48%0.66%1.00%1.65%2.28%3.58%6.19%8.77%11.81%15.27%18.31%19.83%19.57%14.99%
Steroid0.27%0.35%0.44%0.59%0.72%0.91%1.23%1.64%2.18%2.99%3.60%3.80%3.48%2.50%
Anticoagulants20.01%0.01%0.03%0.04%0.06%0.09%0.15%0.23%0.32%0.47%0.68%0.88%0.68%0.46%
SSRI0.16%0.17%0.15%0.21%0.24%0.29%0.38%0.41%0.59%0.92%1.23%1.57%1.88%1.41%
No. of risk factors
≥ 111.53%15.26%16.72%19.63%25.88%30.45%40.22%49.00%58.39%64.43%70.27%70.69%67.59%54.93%
≥ 21.66%2.42%3.23%4.36%6.59%9.35%14.79%20.87%28.01%33.92%39.74%40.03%36.67%25.34%
≥ 30.16%0.25%0.39%0.67%1.22%2.10%3.92%6.44%10.06%13.44%17.08%16.97%15.05%8.48%
No. of risk factors
(After H. pylori prevalence imputation)
≥ 134.84%37.72%51.60%53.61%64.84%67.08%76.84%80.34%83.99%86.35%87.86%87.91%86.93%82.20%
≥ 24.24%5.79%8.93%10.81%16.85%20.48%30.34%38.05%46.72%52.90%57.54%57.88%54.60%42.92%
≥ 30.54%0.83%1.60%2.26%4.04%5.87%10.63%15.35%21.22%26.20%30.43%30.36%27.95%18.31%